Epicardial ablation may not be necessary in all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and frequent ventricular tachycardia

Affiliations

Comment

A Müssigbrodt et al. Europace. 2017.

. 2017 Dec 1;19(12):2047.

doi: 10.1093/europace/eux004.

¹ Department of Electrophysiology, Heart Centre Leipzig, University Leipzig, Strümpellstr. 39, Leipzig 04289, Germany.

No abstract available

Comment in

Epicardial ablation may not be necessary in all patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy and frequent ventricular tachycardia: author's reply.
Berruezo A, Acosta J, Fernández-Armenta J. Berruezo A, et al. Europace. 2017 Dec 1;19(12):2047-2048. doi: 10.1093/europace/eux056. Europace. 2017. PMID: 28419233 No abstract available.

Safety, long-term outcomes and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy. Impact of arrhythmic substrate distribution pattern. A prospective multicentre study.
Berruezo A, Acosta J, Fernández-Armenta J, Pedrote A, Barrera A, Arana-Rueda E, Bodegas AI, Anguera I, Tercedor L, Penela D, Andreu D, Perea RJ, Prat-González S, Mont L. Berruezo A, et al. Europace. 2017 Apr 1;19(4):607-616. doi: 10.1093/europace/euw212. Europace. 2017. PMID: 28431051 Clinical Trial.